Key Takeaways:
- Biocon inaugurates its first US-FDA-approved formulations plant in Cranbury, New Jersey.
- Facility operated by Biocon Generics Inc., having an annual capacity of around 2 Billion oral solid dosage tablets.
- USD 30 Million investment in upgrades since acquiring the plant from Eywa Pharma in 2023.
- Strengthens Biocon’s US presence, ensuring supply resilience and faster access to affordable therapies.
- Inauguration attended by Governor Phil Murphy, Biocon leadership, industry partners, and healthcare stakeholders.
A Milestone in Biocon’s Global Expansion
Biocon has announced the official opening of its first manufacturing plant in the United States, marking a major step in its international growth strategy. Located in Cranbury, New Jersey, the facility is operated by Biocon Generics Inc., a wholly owned subsidiary of Biocon, and has received US-FDA approval to produce oral solid dosage formulations.
The site, which boasts an annual production capacity of around 2 Billion tablets, was acquired from Eywa Pharma in 2023. Since then, Biocon has invested approx USD 30 Million in upgrades to establish a state-of-the-art, vertically integrated manufacturing hub.
Ceremony with Distinguished Guests
The inauguration ceremony was attended by New Jersey Governor Phil Murphy, Biocon Chairperson Kiran Mazumdar-Shaw, CEO and Managing Director Siddharth Mittal, and a gathering of healthcare leaders, customers, and partners.
Governor Murphy commended the company’s decision to choose New Jersey as its US manufacturing base, highlighting the state’s reputation as a hub for life sciences and innovation. “This facility underscores New Jersey’s role as the medicine chest to the world,” he remarked.
Strengthening Supply Chains and Patient Access
Speaking at the event, Biocon Group Chairperson Kiran Mazumdar-Shaw said, “This facility is more than a milestone—it reaffirms our purpose of serving patients wherever they are. It represents our long-term commitment to deeper collaboration with healthcare providers, innovators, and communities to build a healthier, more equitable future.”
CEO Siddharth Mittal added that the proximity to the US market would enable Biocon to deliver high-quality, affordable medicines more efficiently, while reinforcing supply chain resilience. Several products have already been commercialized from the site, with more in development.
Strategic Importance for US Operations
The new Cranbury facility expands Biocon’s global footprint while diversifying its manufacturing base. It is expected to enhance the reliability of supply for patients in the US and accelerate access to essential therapies. Beyond serving the domestic market, the plant is also poised to support Biocon’s international distribution network.
